Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Center Secures $3 Million More In Budget Agreement; Boosts For NIH, Cybersecurity

This article was originally published in The Gray Sheet

Executive Summary

FDA’s Center for Devices and Radiological Health will gain $3 million more in funding compared to 2015, NIH will get a $2 billion boost, and Precision Medicine and BRAIN initiatives will be well-funded under a budget agreement reached by Congress Dec. 15, slated for Congress’ approval in the next several days.

You may also be interested in...



NIH Highlights Advanced Imaging, Neurostim Technologies In Funding Appeal

Further development of medical technologies to advance brain disease diagnoses, treat spinal cord injuries and manage pain without the use of addictive opioids would be key beneficiaries if additional funding from Congress for the National Institutes of Health comes through, NIH head Francis Collins told appropriators.

Task Force Mammography Guidelines Present Challenges And Opportunities

Mammography coverage policies among public and private payers are not likely to be restricted, at least in the near term, by the U.S. Preventive Services Task Force's new breast cancer screening guidelines, but prospects for longer-term adjustments remain

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

Topics

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel